馃毃 Positive results from the phase 3 VOLGA trial presented at #ESMO26
The VOLGA trial evaluated perioperative durvalumab (D) 卤 tremelimumab (T) plus neoadjuvant enfortumab vedotin (EV) in patients with muscle-invasive bladder cancer (MIBC) who were ineligible for or refused cisplatin and were planned for radical cystectomy.
Both primary EFS endpoints were met:
馃敼 D + EV vs control: HR 0.51; 24-month EFS 64% vs 45%
馃敼 D + T + EV vs control: HR 0.61; 24-month EFS 60% vs 45%
Importantly, D + EV also significantly improved OS, with an HR of 0.58 and 24-month OS rates of 78% vs 69%.
Pathological complete response was 45% with D + EV vs 10% with control.
OS significance was not met for D + T + EV at this interim analysis; follow-up is ongoing.
馃搫 https://www.nejm.org/doi/full/10.1056/NEJMoa2608323?referrer=https%3A%2F%2Ft.co%2F
#ESMO26 #BladderCancer #MIBC #VOLGA
54 views 路 2 likes 路 1 repost 路 0 replies
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgPerioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgTarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgDarolutamide with androgen deprivation therapy (ADT) and definitive or salvage locoregional radiation therapy (RT) for localised, very high-risk prostate cancer: Interim analysis of an international, placebo-controlled, randomised phase 3 t
https://esmocongress.esmo.orgSource: Mirrors of Medicine 路 x.com